Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

Acquisition

11 Dec 2006 07:01

CareCapital Group plc11 December 2006 For release at 0700h, 11 December 2006 CareCapital Group Plc ("CareCapital" or "the Company") Investment and Development Programme in Germany CareCapital Group Plc, the healthcare real estate company which listed on AIM inAugust (CARE), announces that it has completed the acquisition of a majormedical centre in Berlin as the first part of an initial €35 million investmentand development programme in Germany. This first investment, at an acquisition cost of • 9.2 million, is a 4,100 sq mmedical facility housing 34 tenants including physicians, dentists, a dentallab, diagnostic facilities, a pharmacy and other healthcare related retailers.An additional €4.2 million acquisition of a 2,800 sq m medical centre housing 25medical tenants situated to the South East of Berlin together with its adjoiningdevelopment site is scheduled for completion in February 2007. These two investments represent the initial stage of the €35 million programme,on which heads of terms have been agreed with a German developer/constructioncompany, with funding supplied by a major German bank. The programme currentlyincludes two further development sites in the Berlin area. Any additionalfunding for the programme will come from the Company's existing resources andfacilities. The programme enables CareCapital to capitalise on recent changes in Germanlegislation which favour primary care provision from large, integrated medicalcare centres. Michael Sinclair, Chairman, commented: "The investment and development programmein Germany follows extensive research, conducted by CareCapital over the pastmonths and represents an exciting opportunity for the Company. It will notimpact on our development programme in the UK which remains on target. "CareCapital will leverage its UK experience to manage and develop the mixedeconomy healthcare facilities in Germany that will increasingly become a featureof UK primary care provision as services are moved out of the hospitalenvironment to community locations in accordance with Government policy. Inaddition, the programme will bring us high quality assets at yieldssignificantly greater than those currently prevailing in the UK and withsimilarly comparable covenant profiles." For further information please visit www.carecapital.co.uk or contact: CareCapital Group Plc Daniel Stewart & Co. Plc Tavistock CommunicationsPaul Stacey, Managing Director Lindsay Mair, Director - Simon Hudson,Shareen Courtney, Marketing Corporate Finance Richard SunderlandTel: 020 7034 1949 Tel: 020 7776 6550 Tel: 020 7920 3150pstacey@carecapital.co.uk lindsay.mair@danielstewart.co.uk shudson@tavistock.co.ukscourtney@carecapital.co.uk rsunderland@tavistock.co.uk This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
27th Aug 20197:00 amRNSTotal Voting Rights and Directors' Shareholdings
8th Aug 201910:45 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Nearing the end-goal
7th Aug 20197:00 amRNSIssue of equity and new debt facility
6th Aug 201911:05 amRNSSecond Price Monitoring Extn
6th Aug 201911:00 amRNSPrice Monitoring Extension
25th Jul 20195:12 pmRNSResult of AGM
25th Jul 20197:00 amRNSAGM Statement & Technological update
22nd Jul 20197:00 amRNSHarley Street update
28th Jun 20197:00 amRNSFinal Results
3rd Jun 20197:00 amRNSTechnological update
31st May 20195:30 pmRNSTotal Voting Rights
17th May 20195:29 pmRNSHolding(s) in Company
16th May 20192:23 pmEQSAdvanced Oncotherapy (AVO-GB): Strong fundamentals underpin future growth
13th May 201912:20 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Commercialising a breakthrough technology
10th May 20197:00 amRNSDebt facility secured
16th Apr 201910:26 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Preparing for commercialisation
16th Apr 20199:12 amEQSAdvanced Oncotherapy (AVO-GB): Key talent acquisition reaffirms the promise of LIGHT
16th Apr 20197:00 amRNSSenior Management Appointment
7th Mar 20199:00 amRNSPrice Monitoring Extension
22nd Feb 20197:00 amRNSGrant of options
1st Feb 20197:00 amRNSAppointment of Nominated Adviser and Joint Broker
30th Jan 201911:45 amRNSSchedule 2(g) Disclosure
29th Jan 20199:38 amRNSTotal Voting Rights and Significant Shareholdings
24th Jan 201912:14 pmRNSSchedule 2(g) Disclosure
22nd Jan 20193:29 pmRNSResult of General Meeting
21st Jan 201911:15 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Important regulatory milestone: ISO approval
21st Jan 20197:00 amRNSISO 13485:2016 certification for medical devices
21st Dec 201810:15 amRNSLaunch of 2018 SAYE Scheme
21st Dec 20187:00 amRNSProposed Direct Subscription to raise £10.0m
16th Oct 20184:31 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Four components integrated
16th Oct 20183:58 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Treatment planning system agreement
10th Oct 20187:30 amRNSGPSL Research - Flash Note on AVO
10th Oct 20187:00 amRNSTechnological update
4th Oct 201811:07 amRNSGPSL Research - Flash Note on AVO
28th Sep 20187:00 amRNSHalf-year Report
27th Sep 20187:00 amRNSTechnological update
10th Sep 201811:32 amRNSHolding(s) in Company
7th Sep 201811:52 amRNSHolding(s) in Company
3rd Sep 20185:15 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Treatment planning system agreement
3rd Sep 201811:38 amRNSCompletion of the £6.41m Placing
29th Aug 20189:57 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Treatment planning system agreement
28th Aug 20187:00 amRNSDirector Declaration
9th Aug 20187:00 amRNSExercise of Warrants and Issue of Shares
2nd Aug 20187:00 amRNS£6.41m Placing
25th Jul 20183:34 pmRNSResult of AGM
4th Jul 20184:40 pmRNSSecond Price Monitoring Extn
4th Jul 20184:35 pmRNSPrice Monitoring Extension
4th Jul 201811:05 amRNSSecond Price Monitoring Extn
4th Jul 201811:00 amRNSPrice Monitoring Extension
4th Jul 20189:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.